| scholarly article | Q13442814 |
| P2093 | author name string | P Rossing | |
| P2860 | cites work | Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia | Q73313415 |
| Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy | Q73323609 | ||
| Rise in albuminuria and blood pressure in patients who progressed to diabetic nephropathy in the Diabetes Control and Complications Trial | Q73397829 | ||
| Significance of microalbuminuria in long-duration type 1 diabetes | Q73587345 | ||
| Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy | Q73828670 | ||
| Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy | Q73905049 | ||
| Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria | Q74431718 | ||
| Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation | Q74651672 | ||
| Renoprotection in diabetes: genetic and non-genetic risk factors and treatment | Q74828055 | ||
| Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system | Q77310073 | ||
| Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus | Q77597423 | ||
| Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study | Q81364368 | ||
| Biochemical risk markers: a novel area for better prediction of renal risk? | Q81448729 | ||
| Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study | Q81690810 | ||
| The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients | Q81897590 | ||
| Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation | Q24682735 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study | Q28188027 | ||
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
| Smoking is associated with progression of diabetic nephropathy | Q28251046 | ||
| Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage | Q29616101 | ||
| Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data | Q31878962 | ||
| Progression of diabetic nephropathy | Q31904729 | ||
| Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study | Q33776663 | ||
| The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? | Q34021651 | ||
| Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift | Q34274466 | ||
| Diabetic nephropathy. Pathogenetic aspects and cardiovascular risk factors | Q34564096 | ||
| Microalbuminuria: associations with height and sex in non-diabetic subjects | Q35186625 | ||
| Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration | Q35824203 | ||
| The changing epidemiology of diabetic microangiopathy in type 1 diabetes. | Q36178419 | ||
| Low birth weight, nephron number, and kidney disease. | Q36192875 | ||
| Preventing end stage renal disease in diabetic patients--genetic aspect (part I). | Q36223159 | ||
| Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study | Q36600164 | ||
| Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. | Q36600524 | ||
| Short stature and diabetic nephropathy | Q36902189 | ||
| Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study | Q37368689 | ||
| The changing natural history of nephropathy in type I diabetes | Q38520789 | ||
| Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria | Q38638695 | ||
| Glomeruli and blood pressure. Less of one, more the other? | Q39554411 | ||
| Renal mRNA levels as prognostic tools in kidney diseases. | Q39645228 | ||
| Prevention of diabetic renal disease with special reference to microalbuminuria | Q40415958 | ||
| Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy | Q40554813 | ||
| Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients | Q40682400 | ||
| Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury | Q40815745 | ||
| Is diabetic nephropathy an inherited complication? | Q41109741 | ||
| von Willebrand factor and development of diabetic nephropathy in IDDM. | Q41163792 | ||
| Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy | Q41306582 | ||
| Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study | Q42281979 | ||
| Long-term juvenile diabetes treated with unmeasured diet | Q43450445 | ||
| Predicting diabetic nephropathy in insulin-dependent patients | Q71401816 | ||
| Albumin excretion and vascular deaths in NIDDM | Q71564790 | ||
| Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion | Q71622424 | ||
| The acute effect of smoking on systemic haemodynamics, kidney and endothelial functions in insulin-dependent diabetic patients with microalbuminuria | Q71682605 | ||
| Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom | Q71792058 | ||
| Albuminuria and Poor Glycemic Control Predict Mortality in NIDDM | Q71816838 | ||
| Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group | Q71979461 | ||
| Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes | Q72218722 | ||
| Insulin resistance in insulin-dependent diabetic patients with microalbuminuria | Q72235035 | ||
| Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus | Q72528281 | ||
| Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents | Q72559004 | ||
| Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study | Q72678721 | ||
| Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus | Q73005633 | ||
| Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group | Q73250901 | ||
| Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment | Q43458408 | ||
| Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes | Q43511438 | ||
| Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota | Q43571491 | ||
| Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold | Q43651227 | ||
| Preventing diabetic nephropathy: an audit | Q43780268 | ||
| A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes | Q43808972 | ||
| Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study | Q43843249 | ||
| Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study | Q43972605 | ||
| Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy | Q44007504 | ||
| Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury | Q44044855 | ||
| Optimal dose of losartan for renoprotection in diabetic nephropathy | Q44082707 | ||
| Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study | Q44091682 | ||
| Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study | Q44105866 | ||
| Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study | Q44262753 | ||
| Effectiveness of aldosterone blockade in patients with diabetic nephropathy | Q44269017 | ||
| Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 | ||
| Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy | Q44390528 | ||
| Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? | Q44418831 | ||
| Regression of microalbuminuria in type 1 diabetes | Q44467189 | ||
| Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. | Q45155019 | ||
| The predictive value of microalbuminuria in IDDM. A five-year follow-up study | Q45197834 | ||
| Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. | Q45242324 | ||
| Renal protective effect of enalapril in diabetic nephropathy | Q46080832 | ||
| Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns | Q46545493 | ||
| Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy | Q46618639 | ||
| Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria | Q46654200 | ||
| Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study | Q46670272 | ||
| Beneficial impact of spironolactone in diabetic nephropathy | Q46826573 | ||
| Low Birth Weight: A Risk Factor for Development of Diabetic Nephropathy? | Q47343236 | ||
| Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study | Q47412001 | ||
| Reversal of lesions of diabetic nephropathy after pancreas transplantation | Q47879758 | ||
| Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes | Q48650978 | ||
| Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study | Q50584833 | ||
| The Natural Course of Microalbuminuria in Insulin‐dependent Diabetes: A 10‐year Prospective Study | Q50595598 | ||
| Meta analysis. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene | Q57389789 | ||
| Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy | Q60218010 | ||
| Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment | Q60218011 | ||
| Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients | Q60218014 | ||
| Smoking and Progression of Diabetic Nephropathy in Type 1 Diabetes | Q61948406 | ||
| Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy | Q67191592 | ||
| Familial Clustering of Cardiovascular Disease in Patients with Insulin-Dependent Diabetes and Nephropathy | Q67745344 | ||
| Ambulatory blood pressure in microalbuminuric type 1 diabetic patients | Q68028526 | ||
| Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes | Q68182150 | ||
| Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria | Q68582537 | ||
| Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus | Q68921607 | ||
| Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes | Q69759022 | ||
| A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy | Q70153357 | ||
| Monitoring glomerular function in diabetic nephropathy. A prospective study | Q70425402 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 11-19 | |
| P577 | publication date | 2005-12-09 | |
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. | |
| P478 | volume | 49 |
| Q61446484 | Are blood lipids associated with microvascular complications among type 2 diabetes mellitus patients? A cross-sectional study in Shanghai, China |
| Q38900912 | Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. |
| Q33854492 | Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes |
| Q35990916 | Comparison of different blood pressure indices for the prediction of prevalent diabetic nephropathy in a sub-Saharan African population with type 2 diabetes. |
| Q36466019 | Comprehensive approach to diabetic nephropathy |
| Q80505006 | Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation |
| Q27012546 | Diabetic kidney disease: a report from an ADA Consensus Conference |
| Q43679311 | Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted? |
| Q35903097 | Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides |
| Q40599056 | Earlier intensified insulin treatment of Type 1 diabetes and its association with long-term macrovascular and renal complications |
| Q55340247 | Elevated urinary N-acetyl-β-D-glucosaminidase is associated with high glycoalbumin-to-hemoglobin A1c ratio in type 1 diabetes patients with early diabetic kidney disease. |
| Q51921253 | Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. |
| Q33479791 | Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus |
| Q40139541 | Future strategies to prevent renal microvascular disease complications in diabetes. |
| Q35976961 | HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study |
| Q44682506 | Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes |
| Q57711927 | How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS |
| Q28080717 | Improvements in the Management of Diabetic Nephropathy |
| Q36796750 | Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease |
| Q36117573 | Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathy |
| Q37780987 | Microvascular disease in children and adolescents with type 1 diabetes and obesity |
| Q37848045 | Need for better diabetes treatment for improved renal outcome |
| Q84006151 | Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients |
| Q36648858 | Preventing microalbuminuria in patients with type 2 diabetes |
| Q50131991 | Proteome Profiling of Diabetic Mellitus Patient Urine for Discovery of Biomarkers by Comprehensive MS-Based Proteomics |
| Q36670632 | Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre |
| Q37960812 | Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease |
| Q42711742 | Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats |
| Q64240851 | The Effect of Vitamin D on Cellular Pathways of Diabetic Nephropathy |
| Q34503796 | The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system |
| Q57718003 | The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood |
| Q33942688 | The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes |
| Q61948368 | UACR—two risk markers or a 24 h collection in a minute? |
| Q36410737 | Urinary proteomics for early diagnosis in diabetic nephropathy |
| Q26858877 | Why do some patients with type 1 diabetes live so long? |
Search more.